药物信息为Migranal (dihydroergotamine mesylate, USP) Nasal SprayThe solution used in Migranal (dihydroergotamine mesylate, USP) Nasal Spray (4 mg/mL) is intended for intranasal use and must not be injected. Rx Only (Valeant Pharmaceuticals North America): WARNING
- WARNING
- DESCRIPTION
- CLINICAL PHARMACOLOGY
- INDICATIONS AND USAGE
- CONTRAINDICATIONS
- WARNINGS
- ADVERSE REACTIONS
- DRUG ABUSE AND DEPENDENCE
- OVERDOSAGE
- DOSAGE AND ADMINISTRATION
- HOW SUPPLIED
- Patient Information
- Diseases/Conditions Related to Migranal (dihydroergotamine mesylate, USP) Nasal SprayThe solution used in Migranal (dihydroergotamine mesylate, USP) Nasal Spray (4 mg/mL) is intended for intranasal use and must not be injected. Rx Only (Valeant Pharmaceuticals North America)
- 外部链接相关的Migranal (dihydroergotamine mesylate, USP) Nasal SprayThe solution used in Migranal (dihydroergotamine mesylate, USP) Nasal Spray (4 mg/mL) is intended for intranasal use and must not be injected. Rx Only (Valeant Pharmaceuticals North America)
Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of DIHYDROERGOTAMINE with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. Because CYP 3A4 inhibition elevates the serum levels of DIHYDROERGOTAMINE, the risk for vasospasm leading to cerebral ischemia and/or ischemia of the extremities is increased. Hence, concomitant use of these medications is contraindicated.(See also CONTRAINDICATIONS and WARNINGS section)
- Drug Information Provided by National Library of Medicine (NLM).
这个站点被设计主要作为提示系统供合格的医师和其他医疗专家使用。 通过使用这个站点您了解并且接受DiagnosisPro.com不会使用作为一个诊断决策系统，并且不能使用做一个临床诊断或替换或者否决一位被准许的医疗保健专家的评断或临床诊断 (充分的使用条款). 我们遵循健康网络基金会的 医学和健康网站的行为准则. 点击这里核实
© 2012 MedTech USA, Inc. (最后更新在05/25/12)
